Topics

Neoadjuvant Palbociclib/Pertuzumab Regimen Active in ER/HER2-Positive Breast Cancer

11:02 EST 2 Feb 2018 | OncLive

The neoadjuvant combination of palbociclib (Ibrance), pertuzumab (Perjeta), fulvestrant (Faslodex), and trastuzumab (Herceptin), cut expression of Ki67 and induced an overall clinical response of 29% in women with ER-positive/HER2-positive breast cancer.

Original Article: Neoadjuvant Palbociclib/Pertuzumab Regimen Active in ER/HER2-Positive Breast Cancer

NEXT ARTICLE

More From BioPortfolio on "Neoadjuvant Palbociclib/Pertuzumab Regimen Active in ER/HER2-Positive Breast Cancer"

Quick Search

Relevant Topic

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...